MA46888A - Inhibiteurs de gsk-3 - Google Patents

Inhibiteurs de gsk-3

Info

Publication number
MA46888A
MA46888A MA046888A MA46888A MA46888A MA 46888 A MA46888 A MA 46888A MA 046888 A MA046888 A MA 046888A MA 46888 A MA46888 A MA 46888A MA 46888 A MA46888 A MA 46888A
Authority
MA
Morocco
Prior art keywords
gsk
inhibitors
Prior art date
Application number
MA046888A
Other languages
English (en)
Inventor
Vijay T Ahuja
Gene M Dubowchik
Richard A Hartz
John E Macor
Prasanna Sivaprakasam
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA46888A publication Critical patent/MA46888A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA046888A 2016-11-28 2017-11-27 Inhibiteurs de gsk-3 MA46888A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662426630P 2016-11-28 2016-11-28

Publications (1)

Publication Number Publication Date
MA46888A true MA46888A (fr) 2021-06-02

Family

ID=60655129

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046888A MA46888A (fr) 2016-11-28 2017-11-27 Inhibiteurs de gsk-3

Country Status (8)

Country Link
US (1) US10774086B2 (fr)
EP (1) EP3544980B1 (fr)
JP (1) JP6977038B2 (fr)
KR (1) KR102611539B1 (fr)
CN (1) CN110225912B (fr)
ES (1) ES2896938T3 (fr)
MA (1) MA46888A (fr)
WO (1) WO2018098411A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3920885A1 (fr) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Composés d'acide valproïque et agonistes wnt pour le traitement de troubles de l'oreille
CN111620881B (zh) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29823A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
WO2007083978A1 (fr) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Dérivés d'imidazopyridine inhibant l'activité de la protéine kinase, méthode de préparation de ces derniers et composition pharmaceutique les comprenant
CN101528729A (zh) * 2006-08-23 2009-09-09 辉瑞产品公司 作为gsk-3抑制剂的嘧啶酮化合物
CA2693232A1 (fr) * 2007-07-18 2009-01-22 Novartis Ag Composes heteroaryliques bicycliques et leur utilisation comme inhibiteurs de kinase
HUE026323T2 (en) * 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as akt kinase inhibitors
RU2014120180A (ru) * 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и аналоги в качестве модуляторов сиртуина
AU2014347027A1 (en) * 2013-11-06 2016-06-23 Bristol-Myers Squibb Company GSK -3 inhibitors

Also Published As

Publication number Publication date
CN110225912B (zh) 2022-10-21
KR20190085112A (ko) 2019-07-17
ES2896938T3 (es) 2022-02-28
KR102611539B1 (ko) 2023-12-06
EP3544980B1 (fr) 2021-10-13
WO2018098411A1 (fr) 2018-05-31
CN110225912A (zh) 2019-09-10
JP2019535790A (ja) 2019-12-12
JP6977038B2 (ja) 2021-12-08
US20190276463A1 (en) 2019-09-12
US10774086B2 (en) 2020-09-15
EP3544980A1 (fr) 2019-10-02

Similar Documents

Publication Publication Date Title
IL263586A (en) Inhibitors of the menin-mll interaction
IL269196A (en) Novel inhibitors
EP3541932A4 (fr) Inhibiteurs de crispr-cas9
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
DK3442972T3 (da) Bromdomænehæmmere
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3571192T3 (da) Jak1-selektive inhibitorer
EP3347008A4 (fr) Inhibiteurs de bêta-lactamases
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
MA53944A (fr) Inhibiteurs de la glycosidase
EP3313828A4 (fr) Inhibiteurs de métallo-bêta-lactamases
MA46855A (fr) Inhibiteurs de magl
MA46857A (fr) Inhibiteurs de magl
EP3541822A4 (fr) Inhibiteurs de magl
DK3335532T3 (da) Tandharve
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA46889A (fr) Inhibiteurs de gsk-3
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
EP3600301A4 (fr) Inhibiteurs de kdm4
DK3481826T3 (da) Tyrosinkinaseinhibitorer
EP3519429A4 (fr) Inhibiteurs bactériens